Effects of HSYA on serum and brain cholesterol levels in AD rats based on quantitative proteomics

References

• Feng YS, Tan ZX, Wu LY, et al. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev. 2020;64:101192.
   PubMed Web of Science ®Google Scholar
• Patterson C. World Alzheimer report 2018: the state of the art of dementia research: new frontiers. London (UK): Alzheimer’s Disease International (ADI), 2018.
   Google Scholar
• Peprah K, McCormack S. Medical cannabis for the treatment of dementia: a review of clinical effectiveness and guidelines. [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. Jul 17.
   Google Scholar
• Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol. 2021;167:382–394.
   PubMed Web of Science ®Google Scholar
• Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12(5):284–296.
   PubMed Web of Science ®Google Scholar
• Ou Z, Deng L, Lu Z, et al. Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer’s disease. Nutr Diabetes. 2020;10(1):12. Apr 22
   PubMed Web of Science ®Google Scholar
• Wang C, Shou Y, Pan J, et al. The relationship between cholesterol level and Alzheimer’s disease-associated APP proteolysis/Aβ metabolism. Nutr Neurosci. 2019;22(7):453–463. Jul
   PubMed Web of Science ®Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2001;8(5):890–899. Oct
   PubMed Web of Science ®Google Scholar
• Lin B, Hasegawa Y, Takane K, et al. High-fat-diet intake enhances cerebral amyloid angiopathy and cognitive impairment in a mouse model of Alzheimer’s disease, independently of metabolic disorders. JAHA. 2016;5(6):e003154.
   Google Scholar
• Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease - epidemiological evidence. Acta Neurol Scand Suppl. 2006;185:50–57.
   PubMedGoogle Scholar
• Sjögren M, Mielke M, Gustafson D, et al. Cholesterol and Alzheimer’s disease-is there a relation? Mech Ageing Dev. 2006;127(2):138–147.
   PubMed Web of Science ®Google Scholar
• Lu YQ, Luo Y, He ZF, et al. Hydroxysafflor yellow a ameliorates homocysteine-induced Alzheimer-like pathologic dysfunction and memory/synaptic disorder. Rejuvenation Res. 2013;16(6):446–452.
   PubMed Web of Science ®Google Scholar
• Wang X, Ma Z, Fu Z, et al. Hydroxysafflor yellow a protects neurons from excitotoxic death through inhibition of NMDARs. ASN Neuro. 2016;8(2):175909141664234.
   Web of Science ®Google Scholar
• Hou J, Wang C, Zhang M, et al. Safflower yellow improves the synaptic structural plasticity by ameliorating the disorder of glutamate circulation in Aβ1-42-induced AD model rats. Neurochem Res. 2020;45(8):1870–1887.
   PubMed Web of Science ®Google Scholar
• Shen WX, Chen JH, Lu JH, et al. TGF-β1 protection against Aβ1-42-induced neuroinflammation and neurodegeneration in rats. Int J Mol Sci. 2014;15(12):22092–22108.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou Z, Zhai W, et al. Safflower yellow attenuates learning and memory deficits in amyloid β-induced Alzheimer’s disease rats by inhibiting neuroglia cell activation and inflammatory signaling pathways. Metab Brain Dis. 2019;34(3):927–939. Jun
   PubMed Web of Science ®Google Scholar
• Michihara A, Sawamura M, Yamori Y, et al. Difference in subcellular distribution between 45- and 37-kDa mevalonate pyrophosphate decarboxylase in rat liver. Biol Pharm Bull. 2001;24(12):1347–1350.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447–1451.
   PubMed Web of Science ®Google Scholar
• Lesser G, Kandiah K, Libow LS, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12(2):138–145.
   PubMed Web of Science ®Google Scholar
• Du C, Hou J, Wang C, et al. Effects of safflower yellow on cholesterol levels in serum and brain tissue of APP/PS1 mice. Metab Brain Dis. 2021;36(4):557–569.
   PubMed Web of Science ®Google Scholar
• Guo T, Zhang D, Zeng Y, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40.
   PubMed Web of Science ®Google Scholar
• Johnson ECB, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020 May;26(5):769–780.
   PubMed Web of Science ®Google Scholar
• Bai B, Wang X, Li Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron. 2020;105(6):975–991.
   PubMed Web of Science ®Google Scholar
• Malik B, Fernandes C, Killick R, et al. Oligomeric amyloid-β peptide affects the expression of genes involved in steroid and lipid metabolism in primary neurons. Neurochem Int. 2012;61(3):321–333. Aug
   PubMed Web of Science ®Google Scholar
• Geifman N, Brinton RD, Kennedy RE, et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):10.
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356(9242):1627–1631. Erratum in: Lancet 2001 Feb 17;357(9255):562.
   PubMed Web of Science ®Google Scholar
• Launer LJ, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001;57(8):1447–1452. Oct 23
   PubMed Web of Science ®Google Scholar
• Björkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res. 2010;51(9):2489–2503.
   PubMed Web of Science ®Google Scholar
• Björkhem I, Heverin M, Leoni V, et al. Oxysterols and Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:43–49.
   PubMedGoogle Scholar
• Bao LD, Wang Y, Ren XH, et al. Hypolipidemic effect of safflower yellow and primary mechanism analysis. Genet Mol Res. 2015;14(2):6270–6278. Jun 11
   PubMed Web of Science ®Google Scholar
• Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195–200. Feb
   PubMed Web of Science ®Google Scholar
• Ghribi O, Larsen B, Schrag M, et al. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol. 2006;200(2):460–467.
   PubMed Web of Science ®Google Scholar
• Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet. 2001;10(12):1317–1324.
   PubMed Web of Science ®Google Scholar
• Kern A, Roempp B, Prager K, et al. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem. 2006;281(5):2405–2413.
   PubMed Web of Science ®Google Scholar
• Kögel D, Deller T, Behl C. Roles of amyloid precursor protein family members in neuroprotection, stress signaling and aging. Exp Brain Res. 2012;217(3–4):471–479.-9.
   PubMed Web of Science ®Google Scholar
• Leong YQ, Ng KY, Chye SM, et al. Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death. Metab Brain Dis. 2020;35(1):11–30. Jan
   PubMed Web of Science ®Google Scholar
• Xiong H, Callaghan D, Jones A, et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and abeta production. Neurobiol Dis. 2008;29(3):422–437. Mar
   PubMed Web of Science ®Google Scholar